Log in

NYSE:DPLO - Diplomat Pharmacy Stock Price, Forecast & News

$4.00
0.00 (0.00 %)
(As of 02/7/2020)
Today's Range
$4.00
Now: $4.00
$4.01
50-Day Range
$3.99
MA: $4.00
$4.00
52-Week Range
$2.43
Now: $4.00
$14.46
Volume744,968 shs
Average Volume545,194 shs
Market Capitalization$304 million
P/E RatioN/A
Dividend YieldN/A
Beta0.82
Diplomat Pharmacy, Inc. operates as an independent specialty pharmacy in the United States. The company operates through Specialty and PBM (pharmacy benefit management) segment. It provides specialty infusion pharmacy, patient care coordination, clinical, compliance and persistency program, patient financial assistance, specialty pharmacy training, benefits investigation, prior authorization, risk evaluation and medication strategy, retail specialty, and hub services, as well as clinical and administrative support services to hospitals and health systems. The company primarily focuses on medication management programs for individuals with complex chronic diseases, including oncology, immunology, hepatitis, multiple sclerosis, specialized infusion therapy, and various other serious or long-term conditions. It also offers PBM services, including electronic point-of-sale pharmacy claims management, retail pharmacy network management, mail pharmacy claims management, specialty pharmacy claims management, Medicare Part D services, benefit design consultation, drug review and analysis, consulting services, data access, and reporting, information analysis, and preferred drug management programs to managed care organizations, self-insured employer groups, unions, and third-party healthcare plan administrators and worker's compensation payers. The company was founded in 1975 and is headquartered in Flint, Michigan.
Read More
Diplomat Pharmacy logo

Industry, Sector and Symbol

Industry Drug stores & proprietary stores
Sub-IndustryN/A
SectorRetail/Wholesale
CUSIPN/A
Phone888-720-4450

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$5.49 billion
Cash Flow$4.60 per share
Book Value$6.24 per share

Profitability

Net Income$-302,270,000.00

Miscellaneous

Employees2,335
Market Cap$304 million
Next Earnings Date5/5/2020 (Estimated)
OptionableOptionable

Receive DPLO News and Ratings via Email

Sign-up to receive the latest news and ratings for DPLO and its competitors with MarketBeat's FREE daily newsletter.


Diplomat Pharmacy (NYSE:DPLO) Frequently Asked Questions

How has Diplomat Pharmacy's stock been impacted by COVID-19 (Coronavirus)?

Diplomat Pharmacy's stock was trading at $4.00 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, DPLO stock has increased by 0.0% and is now trading at $4.00. View which stocks have been mosted impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Diplomat Pharmacy?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Diplomat Pharmacy in the last year. There are currently 2 sell ratings and 5 hold ratings for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Diplomat Pharmacy.

When is Diplomat Pharmacy's next earnings date?

Diplomat Pharmacy is scheduled to release its next quarterly earnings announcement on Tuesday, May 5th 2020. View our earnings forecast for Diplomat Pharmacy.

How were Diplomat Pharmacy's earnings last quarter?

Diplomat Pharmacy Inc (NYSE:DPLO) announced its quarterly earnings data on Tuesday, November, 12th. The company reported ($2.35) EPS for the quarter, missing the Zacks' consensus estimate of ($0.20) by $2.15. The business had revenue of $1.30 billion for the quarter, compared to analyst estimates of $1.17 billion. Diplomat Pharmacy had a negative net margin of 12.47% and a negative return on equity of 12.15%. The business's revenue for the quarter was down 5.3% compared to the same quarter last year. View Diplomat Pharmacy's earnings history.

What price target have analysts set for DPLO?

7 analysts have issued 12-month price objectives for Diplomat Pharmacy's stock. Their forecasts range from $3.00 to $6.00. On average, they expect Diplomat Pharmacy's share price to reach $4.20 in the next twelve months. This suggests a possible upside of 5.0% from the stock's current price. View analysts' price targets for Diplomat Pharmacy.

Has Diplomat Pharmacy been receiving favorable news coverage?

News coverage about DPLO stock has trended very positive this week, according to InfoTrie Sentiment. The research firm ranks the sentiment of media coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Diplomat Pharmacy earned a news sentiment score of 4.0 on InfoTrie's scale. They also assigned headlines about the company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an impact on the company's share price in the near term. View the latest news aboutDiplomat Pharmacy.

Who are some of Diplomat Pharmacy's key competitors?

What other stocks do shareholders of Diplomat Pharmacy own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Diplomat Pharmacy investors own include Bausch Health Companies (BHC), Gilead Sciences (GILD), General Electric (GE), Ford Motor (F), Cara Therapeutics (CARA), Karyopharm Therapeutics (KPTI), CVS Health (CVS), General Motors (GM), Activision Blizzard (ATVI) and Exelixis (EXEL).

Who are Diplomat Pharmacy's key executives?

Diplomat Pharmacy's management team includes the following people:
  • Mr. Brian Thomas Griffin, CEO & Chairman (Age 60)
  • Mr. Philip R. Hagerman, Co-Founder & Chairman Emeritus (Age 67)
  • Mr. Daniel Paul Davison, CFO & Treasurer
  • Mr. Dave Loschinskey, Chief Operating Officer (Age 48)
  • Ms. Terri Anne Powers, VP of Investor Relations

What is Diplomat Pharmacy's stock symbol?

Diplomat Pharmacy trades on the New York Stock Exchange (NYSE) under the ticker symbol "DPLO."

Who are Diplomat Pharmacy's major shareholders?

Diplomat Pharmacy's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Renaissance Technologies LLC (3.36%), State Street Corp (2.69%), Charles Schwab Investment Management Inc. (1.83%), Geode Capital Management LLC (1.01%), Water Island Capital LLC (0.93%) and Bank of New York Mellon Corp (0.86%). Company insiders that own Diplomat Pharmacy stock include Atul Kavthekar, Jeffrey G Park, Kenneth O Klepper, Philip R Hagerman, Regina M Benjamin and Shawn Tomasello. View institutional ownership trends for Diplomat Pharmacy.

Which major investors are selling Diplomat Pharmacy stock?

DPLO stock was sold by a variety of institutional investors in the last quarter, including UBS Group AG, Cambridge Investment Research Advisors Inc., Citigroup Inc., Arizona State Retirement System, Prudential Financial Inc., New York State Common Retirement Fund, Public Sector Pension Investment Board, and State of Tennessee Treasury Department. Company insiders that have sold Diplomat Pharmacy company stock in the last year include Atul Kavthekar, Kenneth O Klepper, and Regina M Benjamin. View insider buying and selling activity for Diplomat Pharmacy.

Which major investors are buying Diplomat Pharmacy stock?

DPLO stock was bought by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Water Island Capital LLC, Gabelli Funds LLC, Dupont Capital Management Corp, Barclays PLC, Goldman Sachs Group Inc., Charles Schwab Investment Management Inc., and SG Americas Securities LLC. View insider buying and selling activity for Diplomat Pharmacy.

How do I buy shares of Diplomat Pharmacy?

Shares of DPLO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Diplomat Pharmacy's stock price today?

One share of DPLO stock can currently be purchased for approximately $4.00.

How big of a company is Diplomat Pharmacy?

Diplomat Pharmacy has a market capitalization of $304 million and generates $5.49 billion in revenue each year. The company earns $-302,270,000.00 in net income (profit) each year or $0.20 on an earnings per share basis. Diplomat Pharmacy employs 2,335 workers across the globe. View additional information about Diplomat Pharmacy.

What is Diplomat Pharmacy's official website?

The official website for Diplomat Pharmacy is http://www.diplomatpharmacy.com/.

How can I contact Diplomat Pharmacy?

Diplomat Pharmacy's mailing address is 4100 S. SAGINAW ST., FLINT MI, 48507. The company can be reached via phone at 888-720-4450 or via email at [email protected]


MarketBeat Community Rating for Diplomat Pharmacy (NYSE DPLO)

Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  372 (Vote Outperform)
Underperform Votes:  398 (Vote Underperform)
Total Votes:  770
MarketBeat's community ratings are surveys of what our community members think about Diplomat Pharmacy and other stocks. Vote "Outperform" if you believe DPLO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe DPLO will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 3/29/2020 by MarketBeat.com Staff

Featured Article: Bar Chart

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel